Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Aptevo Therapeutics Inc.

NASDAQ: APVO · Life Sciences · 11 alerts · CIK 1671584

Share price
$0.5486Close, Nov 16
Market cap
$1.9M
Shares outstanding
3.46MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Aptevo Therapeutics Inc. filings on SEC EDGAR ↗

8:35 AM ET 8-K
Clinical Trial Data

Aptevo Therapeutics Clinical Trial Data

Aptevo Therapeutics presented new preclinical data for its multispecific platform candidates APVO451, APVO452, and APVO711 at the SITC 2026 Annual Meeting. The data demonstrated the molecules' ability to activate immune pathways and promote tumor-cell killing even under immunosuppressive conditions typical of solid tumors. These findings support the continued development of the company's portfolio of CD40-stimulating cancer immunotherapies.

8:37 AM ET 8-K
Clinical Trial Data

Aptevo Therapeutics Clinical Trial Data

Aptevo Therapeutics announced a clinical milestone for mipletamig in frontline AML, achieving a substantial reduction in infusion-related reactions (IRRs) through a refined priming-dose regimen. This optimization, identified through FDA discussions, improves patient tolerability in the ongoing RAINIER study as the company prepares for Phase 2 development.

“We have made substantial progress in improving mipletamig’s tolerability for patients with frontline AML. Mipletamig has demonstrated a differentiated safety and tolerability profile, and successive refinements to the priming-dose regimen have substantially reduced the occurrence of infusion-related reactions. Reducing these reactions matters to patients: it has the potential to make treatment easier to tolerate and limit complications that can disrupt care. These findings are an important part of our preparations for the next stage of clinical development.”

Dirk Huebner, M.D., Chief Medical Officer of Aptevo Therapeutics
8:13 AM ET 8-K
Clinical Trial Data

Aptevo Therapeutics Clinical Trial Data

Aptevo Therapeutics reported clinical data from its Phase 1b RAINIER trial showing that 21% of frontline AML patients treated with mipletamig combination therapy advanced to potentially curative stem cell transplants. This transplant rate compares favorably to historical standard-of-care results (0.7% in the VIALE-A trial) for patients initially deemed unfit for intensive chemotherapy. The company expects to conclude dose optimization by year-end and initiate a Phase 2 trial in the first half of 2027.

8:52 AM ET 8-K
Clinical Trial Data

Aptevo Therapeutics Clinical Trial Data

Aptevo Therapeutics announced it will present data on its multispecific platform and CD40-directed portfolio at the SITC 2026 Annual Meeting. The presentation will focus on the platform's ability to coordinate innate and adaptive immune activity within the tumor microenvironment to overcome immunosuppression in solid tumors.

Counterparty
Society for Immunotherapy of Cancer (SITC)

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.